Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has been assigned a consensus recommendation of “Buy” from the seven ...

Investing.com — Nektar Therapeutics（音译：耐科特治疗公司）的股票面临显著下跌，触及52周低点0.65美元，仅在过去一周就下跌了18.8%。根据 InvestingPro ...

Major indices were in the red early on Tuesday as investors digested a report from the Washington Post that the White House ...

Major indices were in the red early on Monday as market participants patiently awaited clarity on Donald Trump's planned ...

Investing.com — 生物制药公司Nektar Therapeutics (NASDAQ: NKTR )今日宣布与销售代理商Piper Sandler & Co.和BTIG, LLC签订了一项价值高达7500万美元的股权分配协议，此举旨在加强其财务状况。

The interleukin-2 (IL-2) therapies market in the USA is poised for major growth, projected to reach $4 billion by 2034, ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report), with a ...

We recently published a list of 10 Stocks Wall Street Is Calling Bullish Amid Market Turmoil. In this article, we are going ...

Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference: ...

Shares of NKTR stock opened at $0.90 on Thursday. Nektar Therapeutics has a 12 month low of $0.65 and a 12 month high of $1.93. The firm has a market cap of $165.42 million, a PE ratio of -1.07 ...

Fintel reports that on March 14, 2025, Oppenheimer upgraded their outlook for Nektar Therapeutics (NasdaqCM:NKTR) from ...

1 Day NKTR 9.98% DJIA 1.65% Russell 2K 2.53% Health Care/Life Sciences 0.14% ...